Kavalactone

Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC

Retrieved on: 
Thursday, February 29, 2024
PHD, Acquisition, CMO, Biotechnology, Legacy, Marketing, FDA, Active ingredient, Growth, Health, CO2, Kavalactone, Family, Sycamore, Partnership, Retail

MELBOURNE, Fla., Feb. 29, 2024 /PRNewswire/ --  Branded Legacy (OTC.PK: BLEG), Inc., a leading BioTech holdings company, announced today the  signed letter of intent to purchase Sycamore BioPharma, LLC, an established developer of plant based pharmaceuticals. The strategic move aligns with Branded Legacy's commitment to expanding its portfolio in the biotech sector and further solidifies its position as a key player in the industry.

Key Points: 
  • MELBOURNE, Fla., Feb. 29, 2024 /PRNewswire/ --  Branded Legacy (OTC.PK: BLEG), Inc., a leading BioTech holdings company, announced today the  signed letter of intent to purchase Sycamore BioPharma, LLC, an established developer of plant based pharmaceuticals.
  • The strategic move aligns with Branded Legacy's commitment to expanding its portfolio in the biotech sector and further solidifies its position as a key player in the industry.
  • With a commitment to quality, authenticity, and a passion for natural ingredients, Sycamore BioPharma has become a trusted name in the industry.
  • The collaboration between Branded Legacy and Sycamore BioPharma is poised to create synergies across various aspects of the business.

DoubleRainbow Biosciences and Kelai Pharmaceuticals to collaborate on novel natural compound therapeutics

Retrieved on: 
Monday, August 22, 2022
Metabolomics, Plant, Synthetic biology, Research, Mental, Therapy, Impact, PMID, Administration, Advanced Drug Delivery Reviews, Psychopharmacology, ADD, Science, Quality of life, Organization, Double, Government budget balance, Double Rainbow, Kavalactone, GLOBE, Medicine, Addiction, Intellectual property, Genomics, Health, Environment, Life, Patient, Fine chemical, Pharmaceutical industry, Medicinal plants, Disease, Piper

Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.

Key Points: 
  • Lexington, MA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (Double Rainbow), a sustainable biotech company harnessing bioengineering to improve the quality of human health, announced today a new research collaboration with Kelai Pharmaceuticals (Kelai) to explore the potential of biosynthetic kavalactone therapeutics.
  • Using Double Rainbows proprietary HARMONYTM platform, the companies will leverage synthetic biology to help Kelai unlock the potential of these natural compounds through sustainable biosynthetic production.
  • As a company, our mission includes doing no harm in the name of doing good, remarks Dr Jacqueline Jacques, Chief Executive Officer of Kelai Pharmaceutical.
  • The supply chain for a natural molecule could be exhausted with the creation of even one new drug.